Details

---

Checkpoint Inhibitors (PD-1/PD-L1 Immune Checkpoint Inhibitors)

• Function: Relieves the suppression of cancer cells on the immune system, enhancing the body’s natural cancer-fighting ability.

• Indications: Melanoma, non-small cell lung cancer, kidney cancer, cervical cancer, etc.

• Ideal for: PD-L1 positive patients or those who have failed standard treatments.

• Clinical Use: Monotherapy or combination therapy.

---

CAR-T Cell Therapy

• Function: Modifies the patient's T-cells to precisely identify and destroy tumors.

• Indications: Acute lymphoblastic leukemia, B-cell lymphoma, etc.

• Ideal for: Refractory hematological cancers or recurrent cases.

• Clinical Use: Cell-based immunotherapy, bridging therapy.

---

CIK Immunotherapy

• Function: Expands immune cells in vitro and then re-infuses them to enhance immune cell killing power.

• Indications: All solid tumors and some hematologic cancers.

• Ideal for: Patients with low immunity or those requiring postoperative consolidation therapy.

• Clinical Use: Supportive immune therapy, anti-relapse strategy.